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Development of a radionuclide-
labeled monoclonal anti-CD55 
antibody with theranostic potential 
in pleural metastatic lung cancer
So Hee Dho1, Soo Yong Kim1, Chaeuk Chung2, Eun Ha Cho1, So-Young Lee1, Ji Young Kim3, 
Lark Kyun Kim4, Sung-Won Min5, Jichul Lee5, Sung Hee Jung1 & Jae Cheong Lim1
Decay-accelerating factor (CD55 or DAF) inhibits complement-dependent cytotoxicity. We determined 
that CD55 is overexpressed in 76.47% of human non-small cell lung cancer tissue specimens. We 
therefore developed a lutetium-177-labeled chimeric monoclonal antibody against CD55. CD55-
specific single-chain variable fragment (scFv) was selected from a naïve chicken scFv phage-display 
library, converted to IgG, and radiolabeled with lutetium-177 to generate a 177Lu-anti-CD55 antibody. 
We then charaterized the biodistribution of this antibody in a mouse model of pleural metastatic lung 
cancer. The 177Lu-anti-CD55 antibody was primarily retained in tumor tissue rather than normal tissue. 
Treatment of the mice with 177Lu-anti-CD55 reduced the growth of lung tumors and improved median 
survival in vivo by two-fold compared to controls. Finally, 177Lu-anti-CD55 also enhanced the antitumor 
activity of cisplatin both in vitro and in vivo. These data suggest 177Lu-anti-CD55 antibody is a promising 
theranostic agent for pleural metastatic lung cancer.
Pleural metastasis is a frequent cause of pain and dyspnea in patients with advanced cancer. It is correlated with 
a worse prognosis in various tumors including lymphomas and carcinomas of the lung, breast, gastrointestinal 
tract, and ovaries1,2. Lung cancer, especially non-small cell lung cancer (NSCLC) is the most common (37.5%) 
cause of pleural metastasis including malignant pleural effusion3. Treatment of pleural metastasis consists of tube 
thoracostomy and pleurodesis using sclerosing agents such as talc and Viscum album4. However, in many cases, 
pleural metastases are refractory to these treatments because they are not primary systemic therapies that target 
metastatic lung cancer cells. More systemic intrathoracal chemotherapy including hyperthermic chemotherapy 
with cisplatin, doxorubicin, or mitomycin5 has been lagging behind because the result was controversial. To the 
best of our knowledge, there is no successful clinical study associated with systemic targeted immunotherapies on 
pleural metastasis. Targeted immunotherapies such as pembrolizumab have demonstrated efficacy in advanced 
lung cancer6. However, the efficacy is limited by poor penetration in solid tumors7,8. With the exception of hema-
tological malignancies, immunotherapies must penetrate tissue to access target cells9. Catumaxomab is approved 
in the European Union for the treatment of malignant ascites10. The efficacy of catumaxomab is partly due to the 
efficient delivery of the drug to free circulating tumor cells in ascites fluid. Malignant ascites and malignant pleu-
ral effusions both contain floating tumor cells, which could be effectively targeted by immunotherapies.
The efficacy of cancer immunotherapy is enhanced by antibody-drug conjugates such as radionuclides. Zevalin 
(90Y-ibritumomab tiuxetan), a radioimmunotherapeutic, is widely used for the treatment of non-Hodgkin’s lym-
phoma11. Since 177Lu emits both γ- and β- radiation, which may be useful for imaging and treatment, respectively, 
177Lu-labeled radioimmunotherapies have been investigated for theranostic applications11,12.
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CD55 is a glycosylphosphatidylinositol-anchored protein that inhibits complement-mediated lysis through 
dissociation of the C3 and C5 convertases13,14. Inhibition of CD55 was shown to induce apoptosis or growth arrest 
as well as complement-dependent cytotoxicity15. CD55 is frequently overexpressed in lung cancer16, colorectal 
cancer17–19, gastric cancer20, breast cancer21, ovarian cancer22, leukemia23, and cervical cancer24. Because inhibi-
tion of CD55 promotes apoptosis, an anti-CD55 antibody has been administered in combination with rituximab, 
herceptin, or surgery, and as a monotherapy in lymphoma25 and gastric cancer26. However, the effects of CD55 
immunotherapy or radioimmunotherapy have not been investigated in pleural metastatic lung cancer. Here, we 
developed and characterized a radionuclide-labeled anti-CD55 monoclonal antibody and evaluated it as a thera-
nostic agent in pleural metastatic lung cancer.
Results
CD55 expression in human lung cancer tissue. We investigated whether CD55 was differentially 
expressed in lung cancer compared to normal tissue using immunohistochemistry. CD55 was expressed in 
68.89% (31/45) of lung cancer tissue specimens (Table 1). Of the 34 NSCLC specimens, 26 (76.47%) were positive 
for CD55 (Table 1 and Supplementary Table S1). It was predominantly expressed on cell membranes (Fig. 1a,ii, 
iii,iv, and v, insets) and in the cytoplasm in NSCLC tissue (Fig. 1a,vi,vii, and viii, insets). In contrast, little to no 
CD55 expression was observed in normal tissue (Fig. 1b). These results suggested that CD55 could be a promising 
target of an immunotherapy in NSCLC.
Development of a novel chimeric anti-CD55-specific monoclonal antibody. We next developed a 
novel chimeric anti-CD55-specific monoclonal antibody constructed from phage-displayed antibody fragments. 
A naïve chicken phage-displayed scFv library was biopanned with recombinant human CD55-coated magnetic 
beads. After four rounds of biopanning, 384 individual clones were selected. Binding reactivity was analyzed by 
phage enzyme-linked immunosorbent assay (ELISA) (Fig. 2a and Supplementary Fig. S1). Three of the clones 
(Ab1, Ab14, and Ab17) were isolated repeatedly and contained distinct HCDR3 sequences. The selected scFv 
clones were then converted to the IgG form. The variable region of either the heavy (VH) or light chain (VL) of 
each clone was combined with the human constant region of the heavy (CH1-3) and light chain (Ckappa), respec-
tively, using PCR. The chicken/human chimeric antibody constructs were cloned into a mammalian expression 
vector and transfected into HEK293F cells for production. The purified IgG clones showed the same binding 
profiles as in the phage ELISA. Ab1 demonstrated higher CD55 binding affinity than Ab14 and Ab17 (Fig. 2b). 
The Ab1 clones demonstrated >99% purity (Fig. 2c). The specificity of the Ab1 anti-CD55 monoclonal antibody 
was confirmed by flow cytometry analysis of CD55-positive H460 cells (NSCLC derived from pleural effusions) 
and CD55-negative H69 cells (small cell lung carcinoma) (Fig. 2d). CD55 expression in lung cancer cell lines was 
validated by immunoblotting with an anti-CD55 antibody (ab54595; Abcam; Supplementary Fig. S2).
Characterization of the 177Lu-DTPA-anti-CD55 antibody in vitro. We radiolabeled the Ab1 
anti-CD55 monoclonal antibody with 177Lu via DTPA and achieved >98% radiochemical purity (Supplementary 
Fig. S3). The Ab1 177Lu-DTPA-anti-CD55 antibody (177Lu-anti-CD55) was stable in serum in vitro (Supplementary 
Fig. S4). Since free 177Lu can deposit in bone27, stability of 177Lu-anti-CD55 adds less hematological toxicity. 
Lindmo cell-binding assays demonstrated an immunoreactive fraction of 78.9 ± 5.4% (Fig. 3a). Additionally, 
177Lu-anti-CD55 bound with high affinity to H460 cells, with a Kd of 7.149 ± 5.144 nmol/L and a Bmax of 
30 ± 7.218 fmol/mg (Fig. 3b). The capacity of CD55 to bind to 177Lu-anti-CD55 antibody was confirmed by com-
petitive binding assays using H460 lung cancer cells with high CD55 expression (CD55high), H358 cells with mod-
erate CD55 expression (CD55mod), and H69 cells with low CD55 expression (CD55low), as well as WI-38 normal 
lung cells with low CD55 expression (CD55low). These results indicated that the binding of the 177Lu-anti-CD55 
antibody to H460 and H358 cells was CD55-specific (Fig. 3c). The binding specificity of the 177Lu-anti-CD55 
antibody was demonstrated by competition assays with an unlabeled anti-CD55 antibody (Fig. 3c). Following 
binding and internalization of 177Lu-anti-CD55, a slow release of radioactivity was observed (Supplementary 
Fig. S5). These results demonstrated that the purity, stability, specific binding activity, and influx-efflux kinetics of 
the anti-CD55 monoclonal antibody were retained after labeling with 177Lu.
Characterization of the 177Lu-anti-CD55 antibody in a mouse model of pleural metastatic lung 
cancer. We next investigated whether 177Lu-anti-CD55 selectively targeted pleural metastatic lung tumors in 
mice. Injection of H460 cells directly into the pleural cavity resulted in the development of pleural metastatic lung 
cancer 10 days post-injection (p.i.) (Supplementary Fig. S6). Pleural metastatic tumors were observed infiltrating 
Lung cancer type
Number of stained tissues Total number of 
positive tissuesStrong Moderate Negative
Cancer 18/45 13/45 14/45 31/45 (68.89%)
 NSCLC 14/34 12/34 8/34 26/34 (76.47%)
 SCLC 0/2 0/2 2/2 0/2
 Metastatic 4/9 1/9 4/9 5/9
Normal 1/10 2/10 7/10 3/10
Table 1. CD55 expression in human lung cancer tissue. Immunohistochemical analysis of CD55 in lung cancer 
compared to normal tissue. Strong, moderate, and negative indicate >50%, 10–50%, and <10% positivity, 
respectively.
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the neighboring lung, chest wall, and bone. Tumors were positive for CD55 expression by immunohistochemistry 
(Supplementary Fig. S7). We evaluated CD55 expression in normal organs of balb/c mice to minimize adverse 
effects before treating the mice with 177Lu-anti-CD55. CD55 expression was not detected in normal tissues as 
expected (Supplementary Fig. S8).
We evaluated the biodistribution (tumor uptake and intratumoral distribution) of the 177Lu-anti-CD55 anti-
body in vivo (Fig. 4a and Table 2). The 177Lu-anti-CD55 antibody was predominantly retained in tumor tissues 
at all time points. The accumulation peaked in tumors to 18.35 ± 3.58% ID (% of initial dose)/g after 24 hours. 
Importantly, 177Lu-anti-CD55 accumulated in pleural metastatic tumors but not in normal lung tissue (Fig. 4b). 
We compared the biodistribution and tumor uptake of 177Lu-anti-CD55 to the non-selective 177Lu-IgG antibody 
(Supplementary Fig. S9). The highest levels of the 177Lu-anti-CD55 antibody in normal organs were observed in 
blood samples (8.70 ± 1.09% ID/g at 24 hours). The levels gradually cleared to 1.49% ID/g by approximately 18 
days, with a half-life of 183 hours (Supplementary Fig. S10). The total residual radioactivity gradually decreased as 
the antibody was cleared (Fig. 4c). The levels of 177Lu-anti-CD55 in tumor tissues were 1.9–4.5 times higher than 
those in blood (Supplementary Fig. S11 and Table 2) and 19.7–199 times higher than those in muscle (Table 2).
Micro-single photon emission computed tomography/computed tomography (SPECT/CT) imaging 
demonstrated high uptake of 177Lu-anti-CD55 in H460-derived tumors in pleural metastatic mice (Fig. 4d). 
Radioactivity was highest in the pleural cavity but was also observed in the spleen and bladder. Clearance of 
177Lu-anti-CD55 from non-CD55-expressing tissues was observed 24 hours p.i. (Fig. 4d, second panel). Reduced 
uptake of 177Lu-anti-CD55 was observed in the control group (Fig. 4d, third panel) compared to the metastatic 
lung cancer group (4.2% vs. 15.3% ID, respectively) after 24 hours (Fig. 4d, second panel). These results demon-
strated that 177Lu-anti-CD55 specifically targeted CD55-expressing metastatic lung cancer cells.
Figure 1. CD55 expression in human lung cancer tissue. (a) Immunohistochemical analysis of CD55 in lung 
tissue. i, normal lung; ii, lung adenosquamous carcinoma; iii, lymph node metastatic carcinoma from lung 
adenocarcinoma; iv, lung mucoepidermoid carcinoma; v, lung squamous cell; vi, lung adenocarcinoma; vii, 
lung large cell carcinoma; viii, lung bronchioloalveolar carcinoma. Scale bars = 100 μm. Insets are magnified 
images demonstrating CD55 expression on the cell membrane and in the cytoplasm. (b) Immunohistochemical 
analysis of CD55 expression in normal organs. i, spleen; ii, lung; iii, skeletal muscle; iv, kidney; v, rectum; vi, 
colon; vii, stomach; viii, liver. Scale bars = 100 μm.
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The 177Lu-anti-CD55 antibody inhibits lung cancer cell invasion and migration in vitro. High 
CD55 expression was observed in metastatic tumor cells (80%, 4/5) compared to NSCLC cells (53.85%, 14/26) 
among CD55-positive cases (Table 1). CD55 was highly expressed at the invading front of the tumor in lung squa-
mous cell carcinoma (Fig. 5a). Therefore, we examined whether 177Lu-anti-CD55 inhibited lung cancer cell inva-
sion and migration in vitro. Treatment of H460 cells with 177Lu-anti-CD55 resulted in a 66.23% reduction in lung 
cancer cell invasion and a 61.51% reduction in migration (Fig. 5b,c). These results suggested that 177Lu-anti-CD55 
could block metastasis of lung cancer cells. However, we did not exclude the possibility that 177Lu-anti-CD55 
inhibited metastasis by decreasing tumor cell viability.
Characterization of the 177Lu-anti-CD55 antibody in lung cancer cells and in a mouse model 
of pleural metastatic lung cancer. Even at low concentrations (5 and 10 µg/ml), where the unlabeled 
anti-CD55 antibody was ineffective in inducing cell death in H460 cells, 177Lu-anti-CD55 reduced cell viability 
by 26.7% and 33.4%, respectively (Fig. 6a). Additionally, 177Lu-anti-CD55 inhibited the survival of H358 cells 
(bronchioloalveolar carcinoma cells, a subtype of NSCLC), while unlabeled CD55-specific antibodies did not 
reduce viability (Fig. 6b). H460-induced metastasis in early pleural metastatic mice was attenuated by treat-
ment with 7.4 MBq of 177Lu-anti-CD55 (Fig. 6c). Mice treated with 177Lu-anti-CD55 demonstrated a 2.15-fold 
increase in median survival compared to controls (47.5 vs. 22 days, respectively) (Fig. 6c). Similarly, treatment 
with 177Lu-anti-CD55 resulted in a 23% increase in the median survival of pleural metastatic mice compared to 
controls (27 vs. 22 days, respectively) (Fig. 6d). The 177Lu-anti-CD55 antibody was more effective against early 
pleural metastatic tumors than advanced.
Figure 2. Development of chimeric CD55-specific monoclonal antibodies. (a) Phage ELISA results for 
individual clones tested against recombinant human CD55. A total of 384 clones were tested for binding to 
recombinant human CD55 (Supplementary Fig. 1). The data for 36 clones are shown. (b) Reactivity of three 
anti-CD55 IgGs to recombinant human CD55 analyzed by antigen-binding ELISA. (c) SDS-PAGE analysis of 
the Ab1 anti-CD55 IgG antibody. (d) Representative flow cytometry analysis of H460 and H69 cells stained with 
the Ab1 anti-CD55 antibody.
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Cisplatin and 177Lu-anti-CD55 have synergistic antitumor effects in vitro and in vivo. Cisplatin 
is widely used for lung cancer treatment4,28,29. We hypothesized that 177Lu-anti-CD55 could enhance the efficacy 
of cisplatin since DNA lesions formed by 177Lu-anti-CD55 and cisplatin are different—double strand breaks30 
and cisplatin-DNA adducts31. Treatment of H460 cells with either 177Lu-anti-CD55 or cisplatin alone reduced cell 
viability by 11.5% and 13.6%, respectively. Combined treatment of H460 cells with both 177Lu-anti-CD55 and cis-
platin reduced cell viability by 44.2%, which was indicative of a synergistic effect (Fig. 7a). Additionally, combined 
treatment of H368 tumor cells with 177Lu-anti-CD55 and cisplatin led to a 47.9% reduction in cell viability, which 
was also indicative of a synergistic effect (Fig. 7b).
Importantly, treatment with 177Lu-anti-CD55 was more effective than cisplatin (Fig. 7c), which is a standard 
treatment choice for patients with pleural metastatic lung cancer. Combined treatment resulted in a 2.54-fold 
Figure 3. Characterization of 177Lu-DTPA-anti-CD55 in vitro. (a) Representative results of three independent 
Lindmo assays to examine binding of 177Lu-anti-CD55 to H460 cells. (b) Representative results of three 
independent saturation binding assays of 177Lu-anti-CD55 in H460 cells. (c) Blocking assays in H460, H358, 
H69, and WI-38 cells (n = 3; **P < 0.01; Student’s t test). The results are presented as the mean ± standard error 
of the mean (SEM; error bars).
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increase in the median survival of early pleural metastatic mice (Fig. 7c) and a 1.39-fold increase in the median 
survival of advanced pleural metastatic mice compared to controls (56 days, 30.5, and 22 days, respectively) 
(Fig. 7d).
Discussion
We demonstrated that 177Lu-anti-CD55 has antitumor efficacy in pleural metastatic lung cancer. We selected 
177Lu, a low energy emitter of both γ- and β-rays, which is favorable for both SPECT imaging and targeted radi-
otherapy of micrometastases and small tumors. Our data indicate the 177Lu labelled anti-CD55 antibody is func-
tionally equivalent to the unlabeled anti-CD55 antibody, suggesting that 68Ga and 89Zr, could also be used for 
targeted radioimmunotherapy or diagnostic imaging.
The development of a fully humanized anti-CD55 antibody and an optimized protocol such as repeated 
administration could enhance the efficacy of 177Lu-anti-CD55. Interestingly, starvation accelerated the uptake of 
177Lu-anti-CD55 by up to 10.47-fold (Supplementary Fig. S12). However, additional studies are required to deter-
mine whether starvation or caloric restriction could improve the efficacy of 177Lu-anti-CD55 in vivo.
We focused on whether 177Lu-anti-CD55 could improve quality of life in advanced lung cancer patients. First, 
we showed that the antibody slowed weight loss, which is correlated with quality of life (Supplementary Fig. S13). 
It may directly attenuate cachexia or act through other factors such as cytokines or neuropeptides32. Second, 
physical isolation for treatment should be reconsidered despite the increase in survival. Thus, we administered 
a reduced dose of 177Lu-anti-CD55 (7.4 MBq, 20 g) to mice compared to that of standard radiopharmaceutical 
therapies. This dose is equivalent to approximately 1.77 GBq per human (60 kg) based on the United States Food 
and Drug Administration guidelines33. In comparison, 7.4 GBq per human was administered as a clinical stand-
ard dose of 177Lu-DOTATATE to treat neuroendocrine tumors. Third, we focused on whether 177Lu-anti-CD55 
demonstrated reduced toxicity. L-lysine and L-arginine can counteract kidney retention of radiopeptides and 
prevent nephrotoxicity34. Although the levels of 177Lu-anti-CD55 in the kidney were not high (2.79–6.19% ID/g), 
we considered the possibility that residual radioactivity could result in toxicity. Additionally, we are currently 
trying to shorten the half-life of 177Lu-anti-CD55 by Ab Fc engineering Chest tube drainage could minimize the 
absorption of 177Lu-anti-CD55 into the blood.
Despite the synergistic antitumor effects of combined cisplatin and 177Lu-anti-CD55 treatment in vitro, pleural 
metastatic mice were less susceptible to combined treatment. We speculate that this may be because we evalu-
ated the effects in an advanced lung cancer model. These tumors may not be as susceptible to combined therapy. 
Given that cisplatin is an effective therapy for early- to advanced-staged lung cancer, combined cisplatin and 
177Lu-anti-CD55 therapy could be effective for various types of lung cancer.
Methods
Immunohistochemistry. Immunohistochemical analysis was performed by SuperBioChips Laboratories 
as previously described35. A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used 
for all analyses. Tissue array slides (CCA4E, lung cancer-metastasis-normal; SuperBioChips Laboratories) from 
multiple lung cancer patients were immunostained and imaged. Formalin-fixed tissue samples from pleural met-
astatic mice were also analyzed by SuperBioChips Laboratories. The analysis was blinded and the quantifica-
tion performed by pathologists. The percentage of positive tissues was scored and classified as follows: ≥50% as 
‘Strong’, 10–50% as ‘Moderate’, and <10% as ‘Negative”.
Selection of CD55-specific scFvs using phage display. A naïve chicken phage-displayed scFv library 
(constructed by SG Medical, Inc. as described previously36,37) was used for bio-panning to select CD55-specific 
scFvs. Briefly, 5 × 106 magnetic beads (Dynabeads M-270 epoxy; Invitrogen) were coated with 2.5 μg of recombinant 
Organ 1 hr 6 hr 24 hr 72 hr 120 hr 168 hr
Blood 3.52 ± 1.94 7.48 ± 1.25 8.70 ± 1.09 6.43 ± 0.36 4.5 ± 0.80 4.00 ± 0.18
Liver 1.24 ± 0.54 3.06 ± 0.77 4.84 ± 0.31 4.30 ± 0.95 4.35 ± 1.2 3.68 ± 0.30
Kidney 3.38 ± 0.57 4.89 ± 1.23 6.19 ± 0.78 4.24 ± 1.02 3.91 ± 0.60 2.79 ± 0.04
Spleen 0.92 ± 0.55 3.03 ± 0.34 6.83 ± 3.58 6.46 ± 2.97 7.57 ± 3.91 5.58 ± 1.83
Stomach 0.12 ± 0.09 0.25 ± 0.05 0.64 ± 0.17 0.86 ± 0.19 0.68 ± 0.16 0.62 ± 0.10
Small Intestine 1.15 ± 0.55 0.60 ± 0.05 0.91 ± 0.14 0.73 ± 0.17 0.72 ± 0.12 0.49 ± 0.02
Large Intestine 0.11 ± 0.04 0.92 ± 0.24 0.97 ± 0.22 1.21 ± 0.69 0.72 ± 0.14 1.32 ± 0.59
Muscle 0.08 ± 0.05 0.10 ± 0.04 0.30 ± 0.03 0.47 ± 0.06 0.43 ± 0.11 0.44 ± 0.14
Femur 0.25 ± 0.17 0.59 ± 0.04 1.39 ± 0.51 1.22 ± 0.32 1.32 ± 0.12 1.22 ± 0.18
Tumor 15.92 ± 8.75 14.59 ± 5.10 18.35 ± 3.58 12.22 ± 1.54 12.22 ± 1.10 8.70 ± 0.20
T/B 4.52 1.95 2.11 1.90 2.72 2.18
T/M 199.00 145.90 61.17 26.00 26.00 19.77
T/L 12.84 4.77 3.79 2.84 2.81 2.36
T/K 4.71 2.98 2.96 2.88 3.13 3.12
Table 2. Biodistribution of the 177Lu-anti-CD55 antibody in a pleural metastatic mouse model. Results are 
expressed as % ID/g ± SD (n = 3). T/B, tumor to blood ratio; T/M, tumor to muscle ratio; T/L, tumor to liver 
ratio; T/K, tumor to kidney ratio.
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human CD55 (2009-CD/CF; R&D Systems) for each round of bio-panning (four rounds). After the final round, 384 
individual phage clones that displayed scFv were randomly selected from colonies grown on output plates and tested 
for reactivity to recombinant human CD55 using a phage enzyme immunoassay. ELISA-positive scFv clones were 
analyzed by DNA sequencing, and three unique scFv clones with different CD55 binding affinities were identified.
Preparation of anti-CD55 IgG. The variable heavy chain gene of selected scFv clones was amplified 
using the primers 5′-GCTAGCCGCCACCATGGGCTGGTCCTGCATC ATCCTGTTCCTGGTGGCCA 
CCGCCACCGGCGCCGTGACGTTGGACGAGTCCGGG-3′ and 5′-GGGCCCTTGGTG GAGGCGGAGG 
AGACGATGACTTCGGTCCC-3′. The variable light chain gene of the clones was amplified using the primers 
5  ′ - A AG C T TG C C G C C AC C ATG G G C TG G TC C TG C ATC ATC C TG T TC C TG G TG G C C AC C G 
CCACCGGCGCCCTGACTCAGCCGTCCTCGGTG-3′ and 5′-GAGGGGGCGGCC ACGGTCCGTAGGACG 
GTCAGGGTTGTCCCGGC-3′. The variable heavy chain primers were designed to add NheI and ApaI restriction 
sites to both the 5′ and 3′ ends. The variable light chain primers were designed to add HindIII and RsrII sites 
Figure 4. Biodistribution analysis of 177Lu-anti-CD55 in vivo. (a) The biodistribution of 177Lu-anti-CD55 in 
tissue from pleural metastatic mice (n = 3–6 per condition). The results are presented as the mean ± SD (error 
bars). (b) The biodistribution of 177Lu-anti-CD55 in normal lung and lung tumor tissue from pleural metastatic 
mice (n = 3–6 per condition; **P < 0.01; Student’s t test). The results are presented as the mean ± SD (error 
bars). (c) Excretion and residual radioactivity after injection of 177Lu-anti-CD55 into mice. (d) Micro-SPECT/
CT images of pleural metastatic or control mice treated with 177Lu-anti-CD55. The amount of radioactivity is 
calculated in MBq/cc.
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to both the 5′ and 3′ ends. PCR fragments were digested with the appropriate restriction enzymes (NEB) and 
cloned into the bicistronic mammalian expression vector pCDNA3.1 (Invitrogen), which encodes the hinge and 
CH2-CH3 domains of human IgG1 downstream of the variable heavy chain cloning site. Anti-CD55 IgGs were 
produced and purified as described previously38.
Cell culture. H460 (ATCC HTB-177), H358 (ATCC CRL5807), and H69 (ATCC HTB-119) cells were main-
tained in RPMI-1640 with 10% FBS. WI-38 (ATCC CCL-75) cells were maintained in DMEM with 10% FBS.
Cell survival was quantified using a microplate reader at 450 nm and the Cell Counting kit-8 (Dojindo 
Molecular Technologies) in the presence of human complement system (S1764; Sigma).
For flow cytometry, the cells were stained with an Alexa Fluor 647-conjugated anti-CD55 antibody (A-20186; 
Molecular Probes; red histograms) or isotype human control IgG (I4506; Sigma; blue histograms) and analyzed 
using a BD FACS Canto II.
Invasion and migration assays were performed using a 24-well Transwell system (3422; Costar) as described 
previously35.
Radiolabeling. The 177Lu-anti-CD55 antibody was prepared as previously described39 with minor modi-
fications. Briefly, an anti-CD55-specific monoclonal antibody was incubated with a 50-fold molar excess of 
[(R)-2-Amino-3-(4-isothiocyanatophenyl) propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid 
(p-SCN-Bn-CHX-A”-DTPA,B-355; Macrocyclics) in 0.1 mol/L NaHCO3 buffer (pH 8.2) and conjugated anti-
bodies purified. The p-SCN-Bn-CHX-A”-DTPA-conjugated anti-CD55 antibody was labeled with 177Lu (Lu-177 
n.c.a.; ITG; half-life, 6.71 days) in 0.1 mol/L ammonium acetate buffer (pH 5.4) for 30 min at room temperature.
The immunoreactivity of 177Lu-anti-CD55 was evaluated using the Lindmo assay as described previously40,41. 
Briefly, H460 cells (0 to 6.0 × 106) were incubated with 0.074 MBq of 177Lu-anti-CD55 for 1 hour. The cells were 
washed and binding specificity analyzed using Scatchard assays. Radioactivity was quantified using a Wallac 
1470 automated gamma counter (PerkinElmer Life Science). Saturation binding analyses were performed as 
described previously42. Blocking assays were performed by plating 1.5 × 105 of the indicated cells in 24-well plates 
Figure 5. Effects of the 177Lu-anti-CD55 antibody on invasion and migration in lung cancer cells. (a) The 
invasive front of squamous cell carcinoma in the lung (arrows). Scale bars = 50 μm. (b) Invasion and migration 
of H460 cells treated with IgG, anti-CD55, or 177Lu-anti-CD55. (c) Invasion and migration were quantified by 
counting cells in ten randomly selected regions (***P < 0.001; Student’s t test). The results are presented as the 
means ± SEM (error bars).
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and incubating them with 0.074 MBq of 177Lu-anti-CD55 in the presence of 50X unlabeled anti-CD55 antibody. 
Non-specific binding was quantified as described previously43.
Animal experiments. Animal care and experimental protocols were approved by the Institutional Animal 
Care and Use Committee at KAERI. All methods were carried out in accordance with relevant guidelines and 
regulations. For induction of the pleural metastatic mouse model, 1 × 107 H460 cells were suspended in 200 μl 
of phosphate-buffered saline (the amount of cells was chosen to mimic early pleural metastasis without sudden 
death of mice within 2 weeks) and injected into the thoracic cavities of male balb/c nude mice. Metastatic tumor 
nodules were observed 10 days post-injection (p.i). Ten days after injection of H460 cells, mice were injected in 
the thoracic cavities with 177Lu-anti-CD55 (7.4 MBq) or cisplatin (5 mg/kg/week) and survival assessed. For the 
early pleural metastatic mouse model, each mouse was coinjected in the thoracic and peritoneal cavities with 
H460 cells and either 177Lu-anti-CD55 (7.4 MBq/mouse; 2 mg/kg) or cisplatin (5 mg/kg/week), respectively. Mice 
were observed daily and body weight measured twice a week. Survival and Kaplan-Meier analyses were per-
formed with GraphPad Prism 5. Log-rank (Mantel-Cox) tests were used to calculate P values for Kaplan-Meier 
analyses.
Biodistribution analysis. Biodistribution analysis of 177Lu-anti-CD55 in the mice was performed as 
described previously42. The 177Lu-anti-CD55 antibody (185 kBq) was injected into the thoracic cavity and the 
biodistribution assessed at 1, 6, 24, 72, 120, and 168 hours after injection. At each time point, the mice were 
sacrificed and the relevant organs or tissues excised and weighed. Blood samples were also collected. Counts 
per minute (cpm) in samples were measured using a Wallac 1470 automated gamma counter (PerkinElmer Life 
Science). The cumulative activity was calculated as the percent of injected radioactivity dose per gram of tissue 
(% ID/g). Residual radioactivity was measured with a dose-calibrator and corrected for physical decay from the 
time of injection. Radioactivity excretion was calculated by subtracting the residual activity from the injected 
radioactivity.
Figure 6. Therapeutic efficacy of the 177Lu-anti-CD55 antibody in vitro and in vivo. (a) Assays of H460 lung 
cancer cell viability after treatment with IgG, 177Lu-IgG, anti-CD55, or 177Lu-anti-CD55. α-CD55 (μg/ml) 
indicates the concentration of all the antibodies, IgG, 177Lu-IgG, α-CD55, and 177Lu-α-CD55. 177Lu-α-CD55 
(MBq) indicates the corresponding amounts of radioactivity of 177Lu-α-CD55 for the indicated concentration 
(n = 3; **P < 0.01; Student’s t test). The results are presented as the mean ± SEM (error bars). (b) Assays of H358 
cell viability after treatment with IgG, 177Lu-IgG, anti-CD55, or 177Lu-anti-CD55 (n = 3; *P < 0.05; Student’s t 
test). The results are presented as the mean ± SEM (error bars). (c) Effects of 177Lu-anti-CD55 on the survival of 
H460 bearing-early pleural metastatic mice (n = 10 for each group; ***P < 0.001; Log-rank (Mantel-Cox) test). 
(d) Effects of 177Lu-anti-CD55 on the survival of pleural metastatic mice (n = 10 for each group; **P < 0.01; 
Log-rank (Mantel-Cox) test).
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Micro-SPECT/CT. The 177Lu-anti-CD55 antibody (7.4 MBq) was injected directly into the thoracic cavity of 
the mice and a 30 min scan was acquired 3 and 24 hours p.i. with a NanoSPECT/CT system (Bioscan) as described 
previously42. Images were acquired using the In Vivo Scope software (Bioscan) and PMOD v3.6.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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